Legal battle over Harry's US visa documents reopens as William meets with young farmers - The Heritage Foundation is fighting ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

Gov. Ned Lamont eyed Medicaid reimbursement rates, a hospital tax restructuring and pharmaceutical costs in his biennial ...

Researchers have revealed novel sequence-structure-property relationships for customizing engineered living materials (ELMs), enabling more precise control over their structure and how they respond to ...

At issue as whether Harry came clean to immigration officials about his cocaine, cannabis and psychedelic mushrooms use, as ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.